Clinical trial NCT05409976: The GORE® VIAFORT Vascular Stent IVC Study
Official title: Evaluation of the GORE® VIAFORT Vascular Stent for Treatment of Symptomatic Inferior Vena Cava Obstruction With or Without Combined Iliofemoral Obstruction
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Venous Thromboses
Venous Disease
Venous Leg Ulcer
Venous Stasis
Venous Ulcer
Venous Stenosis
Venous Occlusion
Vein Thrombosis
Vein Occlusion
Vein Disease
Keywords: VIAFORT
Vein Stent
Venous Thrombosis
Venous Stenosis
Gore
Venous occlusion
Lead sponsor: W.L.Gore & Associates
Sponsor class: INDUSTRY
First posted: 2022-06-08
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: This study is a prospective, multicenter, non-randomized, single-arm study.
Primary purpose: TREATMENT

Brief summary: This study is a prospective, multicenter, non-randomized, single-arm study to evaluate the performance, safety, and efficacy of the GORE® VIAFORT Vascular Stent for treatment of symptomatic inferior vena cava obstruction with or without combined iliofemoral obstruction in adult patients.

Detailed description: A maximum of 35 clinical investigative sites across the U.S., Europe, Australia, and New Zealand will participate in this study. One hundred and eleven subjects are intended to be implanted with the GORE® VIAFORT Vascular Stent in this study, with a limit of 22 treated subjects per site and a minimum of 45 patients treated within the United States. Subjects will be evaluated through hospital discharge and return for follow-up visits at 1, 6, 12, 24, 36, 48, and 60 months post-treatment.

Eligibility criteria: Preoperative Inclusion Criteria:

* Patient is at least 18 years of age.
* Patient is willing and able to comply with all follow-up evaluations as well as any required medication or compression regimen.
* Patient is able to provide informed consent.
* One of the following: Clinical severity class of CEAP 'C' classification ≥3 or rVCSS pain score ≥2.
* Intention to treat the target areas with only the GORE® VIAFORT Vascular Stent.
* Estimated life expectancy ≥1 year.
* Patient is ambulatory (use of assistive walking device such as a cane or walker is acceptable).
* Patient has adequate inflow to the target lesion(s), per investigator/sub-investigator discretion, involving at least a patent femoral or deep femoral vein.

Preoperative Exclusion Criteria:

* Patient is a pregnant or breastfeeding woman, a woman planning to become pregnant through the 12-month visit, or a woman who is unwilling to practice an acceptable method of preventing pregnancy through the 12-month visit.
* Patient has clinically significant (e.g., symptoms of chest pain, hemoptysis, dyspnea, hypoxia, etc.) pulmonary embolism (confirmed via Computed Tomography Angiography) at the time of enrollment.
* Patient has a known uncorrectable bleeding diathesis or active coagulopathy meeting the following definitions: uncorrected INR\>2 (not as a result of warfarin or DOAC therapy), OR platelet count \<50,000 or \>1,000,000 cells/mm3, OR white blood cell count \<3,000 or \>12,500 cells/mm3.
* Patient has impaired renal function (eGFR \<30 mL/min/1.73m2) or is currently on dialysis.
* Patient has uncorrected hemoglobin of \<9 g/dL.
* Patient has known history of antiphospholipid syndrome (APS) or patients with hypercoagulable states that are unwilling to take anticoagulant medications on a long-term basis.
* Patient has known homozygous inherited coagulation defect or Protein C/S deficiency.
* Patient has a planned surgical intervention (other than pre-stenting procedures such as thrombolysis or thrombectomy) within 30 days prior to or within 30 days after the planned study procedure.
* Patient is currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this treatment, in the opinion of the investigator/sub-investigator. Observational studies are permitted.
* Patient has had a previous major (i.e., above the ankle) amputation of the target lower limb.
* Patient has known sensitivity to device materials or contraindication to antiplatelets, thrombolytics, anticoagulants (including patients with known prior instances of Heparin Induced Thrombocytopenia type 2 (HIT-2)), or iodinated contrast.
* Patient has had prior stenting or grafts in the target vessels.
* Patient has a known or suspected active systemic infection at the time of the index procedure. Patients with a chronic infection (e.g., HIV, hepatitis C) that is well controlled under their current treatment regimen may be eligible.
* Patient has known history of intravenous drug abuse within one year of treatment.
* Patient has significant peripheral arterial disease (chronic Rutherford Type 2 or greater, acute Rutherford Type IIa or greater).
* Patient has a BMI \>40.
* Patient is actively undergoing or plans to begin cancer treatment.

Intraoperative Inclusion Criteria:

* Presence of non-malignant obstruction of the inferior vena cava defined as occlusion or at least 50% reduction in target vessel lumen as measured by procedural IVUS and venogram, with or without non-malignant obstruction of the common femoral vein, external iliac vein, and/or common iliac vein.
* Patient can accommodate an appropriately sized GORE® VIAFORT Vascular Stent as per reference vessel diameter (see IFU), as determined by intraoperative IVUS post pre-dilation.
* Patient must have appropriate access vessels to accommodate the delivery sheath for the selected device size.
* Patient has adequate landing zones free from significant disease requiring treatment within the native vessels beyond the proximal and distal margins of the lesion.
* Patient has adequate inflow to the target lesion(s), per investigator/sub-investigator discretion, involving at least a patent femoral or deep femoral vein.
* Lesion can be traversed with a guidewire.
* Disease involves the inferior vena cava and may include iliofemoral segments with intent to stent all affected iliofemoral and caval segments.
* Patient does not have significant (i.e., \>20% residual thrombosis) acute thrombus within the target stent area at the time of investigational device placement. Patients with acute thrombus within the target stent area must have thrombus successfully treated prior to investigational device placement. Successful thrombus treatment is defined as reestablishment of antegrade flow with ≤20% residual thrombosis as confirmed by IVUS and venogram, AND freedom from bleeding, vascular injury, or hemodynamically significant pulmonary embolism. After successful thrombus treatment, investigational device placement can occur within the same procedure.
* Patient does not have an inferior vena cava filter present within the target stent area at the time of investigational device placement. Patients with an inferior vena cava filter present within the target stent area must have the filter successfully removed prior to investigational device placement. Successful removal is defined as removal of the main body of the filter and intra-luminal fragments such that there is minimal risk to luminal integrity per investigator/sub-investigator discretion AND freedom from bleeding, vascular injury, or hemodynamically significant pulmonary embolism. After successful filter removal, investigational device placement can occur within the same procedure.

Primary outcomes:
measure: Composite of efficacy and safety events
timeFrame: 12 months
Secondary outcomes:
measure: Number of subjects with primary patency as confirmed by imaging and adverse events
timeFrame: 60 months
measure: Number of subjects with secondary patency as confirmed by imaging and adverse events
timeFrame: 60 months
measure: Number of subjects with clinically driven target lesion revascularization as confirmed by imaging and adverse events
timeFrame: 60 months
measure: Number of subjects with device fracture as confirmed with imaging
timeFrame: 60 months
measure: Number of subjects with stent embolization as confirmed with imaging
timeFrame: 12 months
measure: Number of subjects with device- or procedure-related death
timeFrame: 30 days
measure: Number of subjects with clinically significant pulmonary embolism as confirmed with imaging and adverse events
timeFrame: 30 days
measure: Number of subjects with device- or procedure-related vascular injury as confirmed with adverse events
timeFrame: 30 days
measure: Number of subjects with device- or procedure-related major bleeding events as confirmed with adverse events
timeFrame: 30 days
measure: Revised Venous Clinical Severity Scale (rVCSS)
timeFrame: 60 months
measure: Revised Venous Clinical Severity Scale (rVCSS) Pain
timeFrame: 60 months
measure: Venous Insufficiency Epidemiological and Economic Study - Quality of Life/Symptoms (VEINES-QOL/Sym) VEINES-QOL/Sym
timeFrame: 60 months
measure: Villalta
timeFrame: 60 months
measure: 5 Level EuroQol-5 Dimension (EQ-5D-5L)
timeFrame: 60 months
measure: Technical success
timeFrame: Index procedure (post-op day 0)
measure: Lesion success
timeFrame: Index procedure (post-op day 0)
measure: Procedural success
timeFrame: Index procedure through hospital discharge (discharge estimated as up to 30 days post-treatment)
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
city: New Haven
country: United States
facility: Yale University
state: Connecticut
city: Washington
country: United States
facility: MedStar Washington Hospital Center
state: District of Columbia
city: Chicago
country: United States
facility: Northwestern
state: Illinois
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
city: New York
country: United States
facility: Mount Sinai Medical Center
state: New York
city: New York
country: United States
facility: Weill Cornell Medical College
state: New York
city: Charlotte
country: United States
facility: Atrium Health-Sanger Heart and Vascular Institute
state: North Carolina
city: Cleveland
country: United States
facility: Cleveland Clinic Foundation
state: Ohio
city: Norfolk
country: United States
facility: Sentara
state: Virginia
city: Adelaide
country: Australia
facility: Flinders Medical Centre
state: South Australia
city: Nedlands
country: Australia
facility: Sir Charles Gairdner Hospital
state: Western Australia
city: Aachen
country: Germany
facility: Universitätsklinikum Aachen
city: Arnsberg
country: Germany
facility: Alexianer Klinikum Hochsauerland GmbH
city: Galway
country: Ireland
facility: University College Hospital GALWAY /Clinical Research Facility Galway
state: Connaught
city: Milan
country: Italy
facility: Ospedale San Raffaele
city: Modena
country: Italy
facility: Hesperia Hospital
city: Auckland
country: New Zealand
facility: Auckland City Hospital
city: Cambridge
country: United Kingdom
facility: Addenbrooke's Hospital
city: London
country: United Kingdom
facility: St Thomas' Hospital
city: Oxford
country: United Kingdom
facility: John Radcliffe - Oxford University Hospitals NHS Foundation Trust
Study officials:
affiliation: Northwestern University
name: Kush Desai, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Guy's and St Thomas' NHS Foundation Trust
name: Stephen Black, MD, FRCS (Ed), FEBVS
role: PRINCIPAL_INVESTIGATOR
References: